Selective inhibition of histone deacetylase 6 (HDAC6) is being recognized as a therapeutic approach for cancers. In this study, we designed a new HDAC6 inhibitor, named Suprastat, using in silico simulations. X-ray crystallography and molecular dynamics simulations provide strong evidence to support the notion that the aminomethyl and hydroxyl groups in the capping group of Suprastat establish significant hydrogen bond interactions, either direct or water-mediated, with residues D460, N530, and S531, which play a vital role in regulating the deacetylase function of the enzyme and which are absent in other isoforms. In vitro characterization of Suprastat demonstrates subnanomolar HDAC6 inhibitory potency and a hundred- to a thousand-fold HDAC6 selectivity over the other HDAC isoforms. In vivo studies reveal that a combination of Suprastat and anti-PD1 immunotherapy enhances antitumor immune response, mediated by a decrease of protumoral M2 macrophages and increased infiltration of antitumor CD8+ effector and memory T-cells.

Bright Minds Biosciences Toronto ON M5H 3V9 Canada

Centre of Molecular Structure Institute of Biotechnology of the Czech Academy of Sciences BIOCEV Prumyslova 595 Vestec 252 50 Czech Republic

Department of Biochemistry and Molecular Medicine The George Washington University Washington District of Columbia 20052 United States

Department of Medicinal Chemistry and Pharmacognosy College of Pharmacy University of Illinois at Chicago Chicago Illinois 60612 United States

Department of Pharmacy School of Pharmaceutical Sciences University of São Paulo São Paulo SP 05508 000 Brazil

Laboratory of Structural Biology Institute of Biotechnology of the Czech Academy of Sciences BIOCEV Prumyslova 595 Vestec 252 50 Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc21012123

003      

CZ-PrNML

005      

20210507103239.0

007      

ta

008      

210420s2020 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1021/acs.jmedchem.0c00567 $2 doi

035    __

$a (PubMed)32815366

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Noonepalle, Satish $u Department of Biochemistry and Molecular Medicine, The George Washington University, Washington, District of Columbia 20052, United States

245    10

$a Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models / $c S. Noonepalle, S. Shen, J. Ptáček, MT. Tavares, G. Zhang, J. Stránský, J. Pavlíček, GM. Ferreira, M. Hadley, G. Pelaez, C. Bařinka, AP. Kozikowski, A. Villagra

520    9_

$a Selective inhibition of histone deacetylase 6 (HDAC6) is being recognized as a therapeutic approach for cancers. In this study, we designed a new HDAC6 inhibitor, named Suprastat, using in silico simulations. X-ray crystallography and molecular dynamics simulations provide strong evidence to support the notion that the aminomethyl and hydroxyl groups in the capping group of Suprastat establish significant hydrogen bond interactions, either direct or water-mediated, with residues D460, N530, and S531, which play a vital role in regulating the deacetylase function of the enzyme and which are absent in other isoforms. In vitro characterization of Suprastat demonstrates subnanomolar HDAC6 inhibitory potency and a hundred- to a thousand-fold HDAC6 selectivity over the other HDAC isoforms. In vivo studies reveal that a combination of Suprastat and anti-PD1 immunotherapy enhances antitumor immune response, mediated by a decrease of protumoral M2 macrophages and increased infiltration of antitumor CD8+ effector and memory T-cells.

650    _2

$a zvířata $7 D000818

650    _2

$a nádorové buněčné linie $7 D045744

650    _2

$a krystalografie rentgenová $7 D018360

650    _2

$a racionální návrh léčiv $7 D015195

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a histondeacetylasa 6 $x antagonisté a inhibitory $x metabolismus $7 D000073864

650    _2

$a inhibitory histondeacetylas $x chemická syntéza $x metabolismus $x terapeutické užití $7 D056572

650    _2

$a lidé $7 D006801

650    _2

$a vodíková vazba $7 D006860

650    _2

$a kyseliny hydroxamové $x chemická syntéza $x metabolismus $x terapeutické užití $7 D006877

650    _2

$a imunologické faktory $x chemická syntéza $x metabolismus $x terapeutické užití $7 D007155

650    _2

$a imunoterapie $7 D007167

650    _2

$a melanom $x farmakoterapie $x terapie $7 D008545

650    _2

$a myši inbrední C57BL $7 D008810

650    _2

$a jaterní mikrozomy $x metabolismus $7 D008862

650    _2

$a simulace molekulární dynamiky $7 D056004

650    _2

$a fenylmočovinové sloučeniny $x chemická syntéza $x metabolismus $x terapeutické užití $7 D010671

650    _2

$a vazba proteinů $7 D011485

650    _2

$a krysa rodu Rattus $7 D051381

655    _2

$a časopisecké články $7 D016428

655    _2

$a Research Support, N.I.H., Extramural $7 D052061

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Shen, Sida $u Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States

700    1_

$a Ptáček, Jakub $u Laboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, Vestec 252 50, Czech Republic

700    1_

$a Tavares, Maurício T $u Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States

700    1_

$a Zhang, Guiping $u Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States

700    1_

$a Stránský, Jan $u Centre of Molecular Structure, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, Vestec 252 50, Czech Republic

700    1_

$a Pavlíček, Jiří $u Centre of Molecular Structure, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, Vestec 252 50, Czech Republic

700    1_

$a Ferreira, Glaucio M $u Department of Pharmacy, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil

700    1_

$a Hadley, Melissa $u Department of Biochemistry and Molecular Medicine, The George Washington University, Washington, District of Columbia 20052, United States

700    1_

$a Pelaez, Guido $u Department of Biochemistry and Molecular Medicine, The George Washington University, Washington, District of Columbia 20052, United States

700    1_

$a Bařinka, Cyril $u Laboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, Vestec 252 50, Czech Republic

700    1_

$a Kozikowski, Alan P $u Bright Minds Biosciences, Toronto, ON M5H 3V9, Canada

700    1_

$a Villagra, Alejandro $u Department of Biochemistry and Molecular Medicine, The George Washington University, Washington, District of Columbia 20052, United States

773    0_

$w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 63, č. 18 (2020), s. 10246-10262

856    41

$u https://pubmed.ncbi.nlm.nih.gov/32815366 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20210420 $b ABA008

991    __

$a 20210507103238 $b ABA008

999    __

$a ok $b bmc $g 1650492 $s 1132502

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2020 $b 63 $c 18 $d 10246-10262 $e 20200902 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049

GRA    __

$a R21 CA184612 $p NCI NIH HHS $2 United States

GRA    __

$a R01 NS079183 $p NINDS NIH HHS $2 United States

GRA    __

$a R43 HD093464 $p NICHD NIH HHS $2 United States

GRA    __

$a R41 AG058283 $p NIA NIH HHS $2 United States

LZP    __

$a Pubmed-20210420